Sign in Register

Drug class

Antineoplastic - Proteasome Enzyme Inhibitors

Antineoplastic proteasome enzyme inhibitors are a class of targeted anticancer therapies that disrupt intracellular protein degradation by inhibiting the enzymatic core of the 26S proteasome complex. Read more about Antineoplastic - Proteasome Enzyme Inhibitors

22 drugs in this class 21 manufacturers

Related classes & indications

Alkylating AgentsOncology & immunomodulators · 192 prescription drugs Antirheumatic Agents (DMARDS, non-Biologic)Oncology & immunomodulators · 179 prescription drugs Multiple MyelomaTop indication · 167 prescription drugs

Showing 10–18 of 22 drugs

Sort

BORTEZOMIB

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1

APOTEX CORP

BORTEZOMIB

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1

BLUEPOINT LABOR

BORUZU (bortezomib)

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1

AMNEAL BIOSCIEN

BORTEZOMIB

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1

ZYDUS PHARMACEU

BORTEZOMIB

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1

ATHENEX PHARMAC

BORTEZOMIB

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1

NOVADOZ PHARMAC

BORTEZOMIB

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1

FOSUN PHARMA US

BORTEZOMIB

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1

SINTETICA US LL

BORTEZOMIB

ANTINEOPLASTIC - PROTEASOME ENZYME INHIBITORS · MULTIPLE MYELOMA ·+1

Hospira

Filter & compare in the drug finder → Opens the drug finder with Antineoplastic - Proteasome Enzyme Inhibitors preselected. Add indication or manufacturer filters there.

About Antineoplastic - Proteasome Enzyme Inhibitors.

Antineoplastic proteasome enzyme inhibitors are a class of targeted anticancer therapies that disrupt intracellular protein degradation by inhibiting the enzymatic core of the 26S proteasome complex.

By blocking the targeted breakdown of polyubiquitinated regulatory and damaged proteins, these agents trigger toxic intracellular protein accumulation, endoplasmic reticulum stress, cell-cycle arrest, and apoptosis in rapidly dividing cells.

This therapeutic class is primarily indicated for the treatment of hematologic malignancies, serving as a foundational component in regimens for multiple myeloma and mantle cell lymphoma.

fpnotebook.com
Antineoplastic proteasome enzyme inhibitors are a class of targeted anticancer therapies that disrupt intracellular protein degradation by inhibiting the enzymatic core of the 26S proteasome complex By blocking the targeted breakdown of polyubiquitinated regulatory and damaged proteins, these agents trigger toxic intracellular protein accumulation, endoplasmic reticulum stress, cell-cycle arrest, and apoptosis in rapidly dividing cells
nih.gov
Antineoplastic proteasome enzyme inhibitors are a class of targeted anticancer therapies that disrupt intracellular protein degradation by inhibiting the enzymatic core of the 26S proteasome complex
rxlist.com
By blocking the targeted breakdown of polyubiquitinated regulatory and damaged proteins, these agents trigger toxic intracellular protein accumulation, endoplasmic reticulum stress, cell-cycle arrest, and apoptosis in rapidly dividing cells This therapeutic class is primarily indicated for the treatment of hematologic malignancies, serving as a foundational component in regimens for multiple myeloma and mantle cell lymphoma
patsnap.com
By blocking the targeted breakdown of polyubiquitinated regulatory and damaged proteins, these agents trigger toxic intracellular protein accumulation, endoplasmic reticulum stress, cell-cycle arrest, and apoptosis in rapidly dividing cells
fda.gov
This therapeutic class is primarily indicated for the treatment of hematologic malignancies, serving as a foundational component in regimens for multiple myeloma and mantle cell lymphoma